UBT251, a novel triple agonist, significantly reduced HbA1c and weight more than semaglutide in T2DM
Background
Current treatments for type 2 diabetes mellitus (T2DM), including GLP-1 receptor agonists, effectively lower glucose and promote weight loss but often face limitations in achieving optimal glycemic control and substantial weight reduction for all patients. There's a persistent clinical need for more potent therapies. Triple agonists, targeting GLP-1R, GIPR, and glucagon receptor, offer a promising strategy by combining the glucose-lowering and insulinotropic effects of GLP-1 and GIP with the energy expenditure and fat-burning properties of glucagon, potentially leading to enhanced metabolic benefits.
Study Design
This multicenter, randomized phase 2 trial enrolled 211 Chinese adults (mean age 48.4 years; 131 male) with type 2 diabetes. Participants received once-weekly subcutaneous UBT251 at doses of 2 mg, 4 mg (initial dose 0.5 mg), 4 mg (initial dose 1 mg), or 6 mg. Control arms included 1 mg semaglutide or placebo. The intervention lasted for 24 weeks, with the primary endpoint being the change in glycated hemoglobin (HbA1c). Secondary endpoints included changes in fasting blood glucose, 2-h postprandial glucose, waist circumference, and body weight.
Results
At week 24, UBT251 demonstrated significant reductions in glycated hemoglobin (HbA1c). Least-squares mean changes ranged from -2.16% (95% CI, -2.39 to -1.92) to -1.98% (95% CI, -2.31 to -1.64) across UBT251 dose groups. In comparison, 1 mg semaglutide achieved a -1.77% (95% CI, -1.99 to -1.54) reduction, and placebo showed -0.66% (95% CI, -0.90 to -0.41). Placebo-adjusted differences for UBT251 ranged from -1.50% to -1.32%, with all comparisons showing statistical significance (p < 0.001).
Key Findings
- UBT251 reduced HbA1c by -2.16% to -1.98% across doses, outperforming -1.77% for 1 mg semaglutide.
- Placebo-adjusted HbA1c reductions for UBT251 ranged from -1.50% to -1.32% (all p < 0.001).
- Weight reduction with UBT251 was significantly greater than both placebo and semaglutide (all p < 0.05).
- UBT251 significantly reduced fasting blood glucose, 2-h postprandial glucose, and waist circumference (all p < 0.001).
- Gastrointestinal events were the most common treatment-emergent adverse events.
Why It Matters
UBT251 represents a significant advancement in the treatment of type 2 diabetes and obesity, offering superior glycemic control and weight reduction compared to existing GLP-1R agonists like semaglutide. For individuals struggling to achieve target HbA1c or substantial weight loss with current therapies, this triple agonist could provide a more potent alternative. The once-weekly subcutaneous dosing maintains convenience. While promising, these are phase 2 results; further phase 3 evaluation is required before UBT251 can be considered for clinical use or integrated into existing protocols. This research highlights the potential of multi-receptor agonism to address unmet needs in metabolic health.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
ubt251
type 2 diabetes
obesity
glp-1 agonist
gip agonist
glucagon agonist
